Tarsus Pharmaceuticals (NASDAQ:TARS) Releases Earnings Results

Tarsus Pharmaceuticals (NASDAQ:TARS) released its quarterly earnings data on Tuesday. The company reported ($0.60) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.08, Zacks reports. The firm had revenue of $66.41 million for the quarter, compared to analysts’ expectations of $58.80 million. Tarsus Pharmaceuticals had a negative net margin of 103.64% and a negative return on equity of 55.86%.

Tarsus Pharmaceuticals Stock Up 1.3 %

Shares of NASDAQ TARS traded up $0.55 during midday trading on Thursday, hitting $43.11. The stock had a trading volume of 129,982 shares, compared to its average volume of 645,264. The business’s 50 day moving average is $51.31 and its 200-day moving average is $43.00. The company has a market cap of $1.65 billion, a P/E ratio of -11.26 and a beta of 1.01. Tarsus Pharmaceuticals has a 52 week low of $20.08 and a 52 week high of $57.28. The company has a quick ratio of 5.38, a current ratio of 5.42 and a debt-to-equity ratio of 0.30.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and set a $73.00 target price on shares of Tarsus Pharmaceuticals in a research note on Wednesday. Barclays cut their target price on shares of Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating on the stock in a research note on Wednesday. Oppenheimer lifted their target price on shares of Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the company an “outperform” rating in a research note on Wednesday, January 22nd. The Goldman Sachs Group lifted their target price on shares of Tarsus Pharmaceuticals from $36.00 to $41.00 and gave the company a “neutral” rating in a research note on Friday, November 15th. Finally, Guggenheim reaffirmed a “buy” rating and set a $78.00 target price (up previously from $75.00) on shares of Tarsus Pharmaceuticals in a research note on Monday. One analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $61.33.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.